SuperworthUsana Health Sciences free cash flow USNA
Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jul 4, 2026
- $15.9M
- Latest quarter, Q2 FY26
- $20.2M
- +180% on a year earlier
- Fiscal year 2025
- $8.5M
- −83% on the year before
Usana Health Sciences' free cash flow was $15.9M over the twelve months to Jul 4, 2026, down 69% on a year earlier.
In its latest quarter, Q2 FY26, it was $20.2M, up 180% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 43% a year on average.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $8.5M | −83% |
| FY2024 | $50.9M | −9% |
| FY2023 | $56.1M | −40% |
| FY2022 | $93.5M | −14% |
| FY2021 | $108.5M | −25% |
| FY2020 | $145.3M | +32% |
| FY2019 | $110.2M | −22% |
| FY2018 | $140.7M | +27% |
| FY2017 | $110.6M | +6% |
| FY2016 | $104.3M | +19% |
| FY2015 | $87.7M | +4% |
| FY2014 | $84.8M | −7% |
| FY2013 | $90.8M | +8% |
| FY2012 | $84.4M | +42% |
| FY2011 | $59.5M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $20.2M | +180% | $15.9M | |
| Q1 FY26 | $7.1M | −44% | $3M | |
| Q4 FY25 | −$6.2M | −255% | $8.5M | |
| Q3 FY25 | −$5.2M | −119% | $18.7M | |
| Q2 FY25 | $7.2M | +35% | $51M | |
| Q1 FY25 | $12.7M | −12% | $49.1M | |
| Q4 FY24 | $4M | −79% | $50.9M | |
| Q3 FY24 | $27.1M | +31% | $65.6M | |
| Q2 FY24 | $5.3M | −10% | $59.3M | |
| Q1 FY24 | $14.5M | +35% | $59.9M | |
| Q4 FY23 | $18.7M | −50% | $56.1M | |
| Q3 FY23 | $20.8M | −19% | $74.6M |
Against its peers
Companies in Chemicals nearest Usana Health Sciences' size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| USNAUsana Health Sciences | 6.2% |
| NAGENiagen Bioscience | n/m |
| FTLFFitlife Brands | 12.8% |
| FTKFlotek Industries | −0.5% |
| CRONCronos | 4.0% |
| BTMDbiote | n/m |
| ROGRogers | 3.7% |
| NGVTIngevity | 6.5% |
| IOSPInnospec | 2.9% |
| Peer median | 3.9% |
Where Usana Health Sciences ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Usana Health Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.